Multi-center Study of Three-Dimensional Transesophageal Echocardiography in Patients With Secondary Mitral Regurgitation
Key facts
- Who runs it
- First Hospital of China Medical University
- Where
- China, Hong Kong, and Taiwan92 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 2,400 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 30 Nov 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Transthoracic and Three-Dimensional Transesophageal Echocardiography
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Atrial Secondary Mitral Regurgitation Group:
- Age 18 years or older
- At least mild atrial secondary mitral regurgitation, meeting all of the following criteria:; Structurally normal mitral valve without primary mitral valve disease; Left ventricular ejection fraction ≥50%, without regional wall motion abnormalities or mitral leaflet tethering; Normal or mildly enlarged left ventricle, meeting either of the following sex-specific criteria:; Left ventricular end-diastolic diameter <56 mm in women or <63 mm in men; Left ventricular end-diastolic volume index <71 mL/m² in women or <79 mL/m² in men; Mitral annular dilatation, defined as an anteroposterior diameter >35 mm, together with left atrial enlargement meeting either of the following criteria:; Left atrial volume index >34 mL/m²; Left atrial anteroposterior diameter >37 mm in women or >39 mm in men
- Undergoing both transthoracic and transesophageal echocardiography, with standardized images retained; Control Group:
- Age 18 years or older
- Undergoing transesophageal echocardiography for clinical indications, such as suspected patent foramen ovale or infective endocarditis
- Transthoracic echocardiography showing no significant abnormalities in cardiac structure or function, with less than mild regurgitation of all cardiac valves; All participants must meet the inclusion criteria for their respective group and provide written informed consent
Who cannot take part
- Previous cardiac valve surgery or catheter-based valve intervention
- Primary mitral regurgitation caused by organic mitral valve disease, including degenerative changes, rheumatic involvement, congenital mitral valve abnormalities, or vegetations
- Moderate or greater aortic valve disease
- Congenital heart disease
- The following exclusion criteria apply to both groups:
- Inadequate three-dimensional transesophageal echocardiographic image quality that precludes reliable assessment of mitral valve structure and motion
- Contraindications to, or inability to tolerate, transesophageal echocardiography
- Refusal to provide written informed consent
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Three-dimensional transesophageal echocardiography (3D-TEE) enables detailed assessment of mitral valve anatomy, annular geometry, and regurgitation. This prospective multicenter observational study will evaluate atrial secondary mitral regurgitation (A-SMR) using 3D-TEE combined with transthoracic echocardiography. The study aims to characterize regurgitation severity and associated factors and compare mitral valve structure and left ventricular function between patients and controls. It will also investigate echocardiographic predictors of clinical outcomes during follow-up.
The 2 groups in the trial
- Atrial Secondary Mitral Regurgitation Group
This group will include 1,600 adults aged 18 years or older with at least mild atrial secondary mitral regurgitation who meet the eligibility criteria. Participants will undergo transthoracic and three-dimensional transesophageal echocardiography to assess mitral valve structure, regurgitation severity, and cardiac function. Transesophageal echocardiography will be performed for clinical indications, without additional transesophageal examinations solely for research. Clinical follow-up will be conducted every three months.
Treatment: Transthoracic and Three-Dimensional Transesophageal Echocardiography
- Control Group
This group will include 800 adults aged 18 years or older undergoing clinically indicated transesophageal echocardiography. Transthoracic echocardiography must show no substantial structural or functional cardiac abnormalities, with less than mild regurgitation of all cardiac valves. Participants must meet the control-group eligibility criteria and have none of the exclusion criteria. Transthoracic and three-dimensional transesophageal echocardiographic images will be analyzed for comparison with the atrial secondary mitral regurgitation group.
Treatment: Transthoracic and Three-Dimensional Transesophageal Echocardiography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Secondary Mitral Regurgitation Assessment Using Three-dimensional Transesophageal Echocardiography: A Multicenter Clinical Study
- Record updated
- 5 November 2026